Last 7 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -15.54 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | |
| P/S Ratio | 1202.16 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | |
| P/B Ratio | 5.47 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 30.4% | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | |
| Operating Margin | -286.5% | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | |
| Net Margin | -276.6% | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|
| ROE | -42.7% | — | — | 22.5% | — | — | — | 23.3% |
| — | — | — | -3.8% | — | — | — | — | |
| ROA | -39.3% | -68.5% | -64.9% | 4.7% | 20.4% | 141.4% | -164.6% | 5.2% |
| — | -148.4% | +60.6% | -9.3% | — | — | — | — | |
| ROIC | -63.3% | — | — | -93.5% | — | — | — | -12.8% |
| — | — | — | -628.8% | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 45.6% YoY to 0.02x, tightening the short-term liquidity position.
| Metric | TTM | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | — | — | 0.00 | — | — | — | — |
| — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | 0.05 | — | — | — | — |
| — | — | — | — | — | — | — | — | |
| Current Ratio | 13.18 | 0.02 | 0.02 | 13.18 | 0.02 | 0.03 | 0.03 | 0.03 |
| — | -45.6% | -16.5% | +39909.9% | — | — | — | — | |
| Quick Ratio | 13.04 | 0.02 | 0.02 | 13.04 | 0.02 | 0.03 | 0.03 | 0.02 |
| — | -45.6% | -16.5% | +53440.8% | — | — | — | — | |
| Interest Coverage | -1893.69 | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — |
Includes 30+ ratios · 7 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonYD Bio Limited Ordinary Shares's current P/E is -15.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
YD Bio Limited Ordinary Shares's current operating margin is -286.5%. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking YD Bio Limited Ordinary Shares's business trajectory between earnings reports.